Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

Summary

Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11). Also administered at each cycle was zofran/Kytril/Anzemet, decadron, and IV atropine. At each cycle, patient exams and interviews as well as lab results were to help the research team to determine the symptomatic side effects of the treatment. Recorded past toxicities were to be compared with current side effects.

Timeline

Start

2006-02

Primary completion

2010-10

Completion

2010-10

Outcome

Outcome not reported

Stopped (Enrollment): “Principal Investigator left Moffitt and study had low accrual.”

Drugs

Indications